Cereno reveals promising data for preclinical CVD candidate
In June, Cereno Scientific presented preclinical data regarding the recently nominated candidate drug CS585 at the EHA Congress. The data indicate that CS585 is able to prevent clotting without increasing the risk of bleeding, thereby being a potential breakthrough treatment for thrombosis. The company has put together a video presentation explaining the results and why they indicate that CS585 has the potential to truly transform CVD treatment.
Cereno Scientific’s objective is to develop innovative treatments for cardiovascular disease (CVD) with better disease-modifying efficacy and fewer side effects for patients suffering from common and rare CVDs compared with today’s alternatives. In addition to candidate CS585, Cereno’s pipeline comprises two HDACi (histone deacetylase inhibitors) that act as epigenetic modulators: CS1 in phase II development for pulmonary arterial hypertension (PAH) and, CS014 currently in preclinical development.
One of the defining pathogenic mechanisms of CVD is thrombosis – the formation of occluding blood clots that cut off blood supply to part of or the whole organ e.g. the heart or the brain leading to a heart attack or stroke, respectively. Today’s thrombosis treatments (Warfarin, Heparin, anti-platelets , or NOACs) are reasonably good at preventing an occluding clot (thrombosis), but they come with a significant risk of bleeding, which in itself could be life-threatening.
Preclinical data is encouraging
The clinical stage Gothenburg-based biotech has put together a broad pipeline of drug candidates with the potential to prevent blood clots while at the same time having low or no risk of bleeding. One of these candidates is CS585, a stable, selective, and potent prostacyclin (IP) receptor agonist. When activated, the IP receptor prevents platelet aggregation in arteries and veins after injury. Therefore, by targeting the IP receptor, CS585 is a strong contender for, in the clinic, preventing serious damage during a threatening occlusive thrombotic event.
In June, Cereno’s Director of Translational Research, Dr Michael Holinstat, presented preclinical data relating to CS585 at the European Hematology Association (EHA) 2022 Hybrid Congress. The data suggests that not only does CS585 have the ability to prevent blood clot formation, but it is able to do so without significantly increasing the risk of bleeding. If these results are replicated in the clinical setting, they would represent a significant breakthrough in the treatment of many CVDs where blood clot (thrombus) formation occurs.
Telling the medical community about the benefits of CS585
Being chosen to give a presentation at EHA is considered a prestigious opportunity within the scientific and medical community as only a few abstracts get handpicked by a committee of experts in the field.
Having received positive feedback at EHA, Cereno has decided to take further steps to engage and be active within the medical community regarding its preclinical assets, which is a key factor for long-term success. This week, the company published a video where Dr Holinstat explains the mechanism of action of CS585 and why it has such high potential in the CVD world. See the video below.
Overall, the CS585 data represents Cereno’s continued dedication to developing more effective disease-modifying CVD treatments. The company aims to move the candidate into clinical development by 2023.
If you missed it, watch a short video of Cereno Scientific from the foundation to executing on the vision to transform the CVD treatment landscape > https://youtu.be/hdXyJY33JA0
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
